17,261 trials
Brain and Central Nervous System Tumors · Lymphoma
Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants
Pancreatic Acinar Cell Carcinoma · Pancreatic Ductal Adenocarcinoma · Recurrent Pancreatic Carcinoma
Primary: Progression-free Survival Using RECIST v. 1.1 — 4.9; 5.2 months
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Brain Cancer · Malignant Glioma
Primary: Number of Participants With Adverse Events — 40 Participants
Pompe Disease
Primary: Number of Participants With Adverse Events. — 5; 5 Participants
Breast Cancer
Primary: Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS) — 11.8; 5.8; 3.6; 3.9 months — p=0.3631
Malaria · Severe Malaria
Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05
Alzheimer Disease
Primary: Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline — 1.251; 0.8741 fold change…
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr — -18.005; -45.029; -64.010; -141.848 mg*hrs/dL — p=0.0435
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Verbal Memory Composite — -.31247583; .33390008; -.05181561 Change in Z score memory composite
Breast Cancer · Metastatic Bone Disease
Primary: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 — -73; -77 Percentage change
Cleft Palates
Primary: Number of Participants With Fistula or Delayed Wound Healing Following Palatoplasty — 3; 2; 18; 21 Participants
Prostate Cancer
Primary: Number and Percentage of Participants With Clinically Meaningful Improvement (Between Baseline and End of Treatment) in Quality-of-Life Determined by the Minimum…